Literature DB >> 8133100

Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel.

K M Zangwill1, R W Stout, G M Carlone, L Pais, H Harekeh, S Mitchell, W H Wolfe, V Blackwood, B D Plikaytis, J D Wenger.   

Abstract

The long-term kinetics of the immunologic response after vaccination of adults with Neisseria meningitidis polysaccharide vaccine is unknown. Total meningococcal anti-capsular antibody response (measured by ELISA) and serum bactericidal activity after routine vaccination with quadrivalent meningococcal vaccine were evaluated in US Air Force personnel. In a retrospective cross-sectional study, blood samples were obtained from approximately 40 personnel before vaccination, at 1 and 4-6 months, and at 2, 3, 4, 6, 8, and 10 years after vaccination. Total anti-group A and -group C capsular antibody levels and bactericidal activity peaked 1 month after vaccination and declined substantially by 2 years. At each interval, significantly higher levels of total antibody and bactericidal activity were detected than before vaccination. Anti-capsular antibodies and bactericidal activity persisted for up to 10 years after immunization. These and further studies on the serologic measure of protection against meningococcal disease are important for evaluation of candidate vaccines and development of recommendations for immunization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8133100     DOI: 10.1093/infdis/169.4.847

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 4.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

6.  Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine.

Authors:  O Pérez; M Lastre; J Lapinet; G Bracho; M Díaz; C Zayas; C Taboada; G Sierra
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Endotoxin release and cytokine production in acute and chronic meningococcaemia.

Authors:  J M Prins; F N Lauw; B H Derkx; P Speelman; E J Kuijper; J Dankert; S J van Deventer
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Should university students be vaccinated against meningococcal disease in Canada?

Authors:  Philippe De Wals
Journal:  Can J Infect Dis       Date:  2004-01

9.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

10.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.